Published/presented combination studies with idelalisib, ibrutinib, and venetoclax in CLL
| Agents . | Reference . | No. of patients . | Response rate . | PFS . | OS . |
|---|---|---|---|---|---|
| Idelalisib + rituximab | 9, 10 | 220 | 77% ORR | 12-mo PFS = 66% | Not reached |
| Idelalisib + bendamustine, bendamustine/rituximab, fludarabine, chlorambucil, or chlorambucil/rituximab | 62 | IB = 18 | 82% ORR; 10% CR | 24-mo PFS = 57% | Not reported |
| IBR = 15 | |||||
| IF = 12 | |||||
| ICh = 15 | |||||
| IChR = 14 | |||||
| Ibrutinib + rituximab | 63 | 40 (36 previously treated) | 95% ORR; 8% CR | 18-mo PFS = 78% | 18-mo OS = 84% |
| Ibrutinib + ofatumumab | 64 | 71 | 83% ORR | 12-mo PFS 85%-90% depending on schedule | Not reported |
| Ibrutinib + lenalidomide | 65 | 11 | 100% ORR | 91% at 263 d | 100% at 263 d |
| Venetoclax + rituximab | 20 | 49 (34 evaluable for response) | 88% ORR; 32% CR/CRi | Not reported | Not reported |
| Agents . | Reference . | No. of patients . | Response rate . | PFS . | OS . |
|---|---|---|---|---|---|
| Idelalisib + rituximab | 9, 10 | 220 | 77% ORR | 12-mo PFS = 66% | Not reached |
| Idelalisib + bendamustine, bendamustine/rituximab, fludarabine, chlorambucil, or chlorambucil/rituximab | 62 | IB = 18 | 82% ORR; 10% CR | 24-mo PFS = 57% | Not reported |
| IBR = 15 | |||||
| IF = 12 | |||||
| ICh = 15 | |||||
| IChR = 14 | |||||
| Ibrutinib + rituximab | 63 | 40 (36 previously treated) | 95% ORR; 8% CR | 18-mo PFS = 78% | 18-mo OS = 84% |
| Ibrutinib + ofatumumab | 64 | 71 | 83% ORR | 12-mo PFS 85%-90% depending on schedule | Not reported |
| Ibrutinib + lenalidomide | 65 | 11 | 100% ORR | 91% at 263 d | 100% at 263 d |
| Venetoclax + rituximab | 20 | 49 (34 evaluable for response) | 88% ORR; 32% CR/CRi | Not reported | Not reported |
CR, complete response; CRi, complete response with incomplete marrow recovery; IB, idelalisib + bendamustine; IBR, idelalisib + bendamustine + rituximan; ICh, idelalisib + chlorambucil; IChR, idelalisib + chlorambucil + rituximab; IF, idelalisib + fludarabine; OR, overall response; ORR, overall response rate.